Identification of a Predictive Biomarker for the Beneficial Effect of Keishibukuryogan, a Kampo (Japanese Traditional)‎ Medicine, on Patients with Climacteric Syndrome

Abstract EN

Keishibukuryogan (KBG; Guizhi-Fuling-Wan in Chinese) is one of the Kampo (Japanese traditional) medicines used to treat patients with climacteric syndrome.

KBG can be used by patients who cannot undergo hormone replacement therapy due to a history of breast cancer.

We evaluated whether cytosine-adenine (CA) repeat polymorphism of the estrogen receptor β gene can be a predictor of the beneficial effect of KBG on climacteric syndrome.

We also investigated the relationship between CA repeat polymorphism, the patients’ profiles, and the therapeutic effect.

We found that CA was an SS, SL, or LL genotype according to the number of repeats.

We studied 39 consecutive patients with climacteric disorders who took KBG for 12 weeks.

The diagnosis of climacteric disorders was made on the basis of the Kupperman index.

KBG significantly improved the patients’ climacteric symptoms (i.e., vasomotor symptoms in the patients with the LL genotype and melancholia in the patients with the SL genotype).

No relationship between the patients’ profiles and CA repeat polymorphism was recognized.

CA repeat polymorphism could thus be a potential biomarker to predict the efficacy of KBG in climacteric syndrome, and its use will help to reduce the cost of treating this syndrome by focusing the administration of KBG on those most likely to benefit from it.